Neurocrine Biosciences | NBIX - Operating Profit


Neurocrine Biosciences reported $219.9M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Exelixis USD 251.34M 15.43M Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Incyte USD 700.4M 376.22M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Prothena USD 25.79M 53M Mar/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Repligen USD 21.13M 1.15M Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Teva Pharmaceutical Industries USD 235M 523M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026